To view this site, you need to have JavaScript enabled in your browser, and either the Flash Plugin or an HTML5-Video enabled browser. Download the latest Flash player and try again.

Looking to JAZZ Up Your Portfolio?

6:25 PM ET Fri, 7 June 2013

Jazz Pharmaceuticals' stock has roared, says Mad Money host Jim Cramer. The company gets 69 percent of its sales from its narcolepsy drug Xyrem which has a wall of patents protecting the drug from competition.